BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood 2016;127:17-28. [PMID: 26504182 DOI: 10.1182/blood-2015-07-657981] [Cited by in Crossref: 100] [Cited by in F6Publishing: 93] [Article Influence: 14.3] [Reference Citation Analysis]
Number Citing Articles
1 Despotovic JM, Grimes AB. Pediatric ITP: is it different from adult ITP? Hematology Am Soc Hematol Educ Program 2018;2018:405-11. [PMID: 30504339 DOI: 10.1182/asheducation-2018.1.405] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
2 Vavassori S, Galson JD, Trück J, van den Berg A, Tamminga RYJ, Magerus-Chatinet A, Pellé O, Camenisch Gross U, Marques Maggio E, Prader S, Opitz L, Nüesch U, Mauracher A, Volkmer B, Speer O, Suda L, Röthlisberger B, Zimmermann DR, Müller R, Diepstra A, Visser L, Haralambieva E, Neven B, Rieux-Laucat F, Pachlopnik Schmid J. Lymphadenopathy driven by TCR-Vγ8Vδ1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome. Blood Adv 2017;1:1101-6. [PMID: 29296752 DOI: 10.1182/bloodadvances.2017006411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
3 Michel M. Adult Evans' Syndrome. Hematology/Oncology Clinics of North America 2022. [DOI: 10.1016/j.hoc.2021.12.004] [Reference Citation Analysis]
4 Kohrogi K, Migita M, Anan T, Sugahara T, Yoshimoto K, Kanegane H, Nakamura K. Successful Artery Embolization in a Patient with Autoimmune Lymphoproliferative Syndrome Associated with Splenic Rupture. J Clin Immunol 2020;40:780-2. [PMID: 32583203 DOI: 10.1007/s10875-020-00809-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Mendonça LO, Matucci-Cerinic C, Terranova P, Casabona F, Bovis F, Caorsi R, Fioredda F, Palmisani E, Grossi A, Guardo D, Bustaffa M, Volpi S, Ceccherini I, Ravelli A, Dufour C, Miano M, Gattorno M. The challenge of early diagnosis of autoimmune lymphoproliferative syndrome in children with suspected autoinflammatory/autoimmune disorders. Rheumatology (Oxford) 2021:keab361. [PMID: 33909886 DOI: 10.1093/rheumatology/keab361] [Reference Citation Analysis]
6 Jiang H, Zhang H, Wang Y, Qi W, Cao Q, Xing L, Fu R, Shao Z, Wang H. Sirolimus for the treatment of multi-resistant pure red cell aplasia. Br J Haematol 2019;184:1055-8. [DOI: 10.1111/bjh.15245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Haeri A, Osouli M, Bayat F, Alavi S, Dadashzadeh S. Nanomedicine approaches for sirolimus delivery: a review of pharmaceutical properties and preclinical studies. Artificial Cells, Nanomedicine, and Biotechnology 2018;46:1-14. [DOI: 10.1080/21691401.2017.1408123] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
8 Palmisani E, Miano M, Micalizzi C, Calvillo M, Pierri F, Terranova P, Lanza T, Lanciotti M, Riccardi F, Todiere A, Zanardi S, Caviglia I, Dufour C, Fioredda F. Clinical features and therapeutic challenges of cytopenias belonging to alps and alps-related (ARS) phenotype. Br J Haematol 2019;184:861-4. [PMID: 29527658 DOI: 10.1111/bjh.15178] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
9 Mantadakis E, Farmaki E. Natural History, Pathogenesis, and Treatment of Evans Syndrome in Children. J Pediatr Hematol Oncol 2017;39:413-9. [PMID: 28654461 DOI: 10.1097/MPH.0000000000000897] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
10 Jasinski S, Weinblatt ME, Glasser CL. Sirolimus as an Effective Agent in the Treatment of Immune Thrombocytopenia (ITP) and Evans Syndrome (ES): A Single Institution’s Experience. Journal of Pediatric Hematology/Oncology 2017;39:420-4. [DOI: 10.1097/mph.0000000000000818] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 4.6] [Reference Citation Analysis]
11 Maggiore R, Grossi A, Fioredda F, Palmisani E, Terranova P, Cappelli E, Lanza T, Pierri F, Guardo D, Calvillo M, Micalizzi C, Beccaria A, Coccia MC, Arrigo S, Dufour C, Ceccherini I, Miano M. Unusual Late-onset Enteropathy in a Patient With Lipopolysaccharide-responsive Beige-like Anchor Protein Deficiency. J Pediatr Hematol Oncol 2020;42:e768-71. [PMID: 31876783 DOI: 10.1097/MPH.0000000000001708] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Long Z, Yu F, Du Y, Li H, Chen M, Zhuang J, Han B. Successful treatment of refractory/relapsed acquired pure red cell aplasia with sirolimus. Ann Hematol 2018;97:2047-54. [DOI: 10.1007/s00277-018-3431-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
13 Neely J, von Scheven E. Autoimmune haemolytic anaemia and autoimmune thrombocytopenia in childhood-onset systemic lupus erythematosus: updates on pathogenesis and treatment. Curr Opin Rheumatol 2018;30:498-505. [PMID: 29979258 DOI: 10.1097/BOR.0000000000000523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
14 Bride K, Teachey D. Autoimmune lymphoproliferative syndrome: more than a FAScinating disease. F1000Res 2017;6:1928. [PMID: 29123652 DOI: 10.12688/f1000research.11545.1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
15 Gupta AO, Jan Boelens J, Ebens CL, Kurtzberg J, Lund TC, Smith AR, Wagner JE, Wynn R, Blazar BR, Orchard PJ. Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders. Bone Marrow Transplant 2021;56:1238-47. [PMID: 33441980 DOI: 10.1038/s41409-020-01179-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Gkirtzimanaki K, Kabrani E, Nikoleri D, Polyzos A, Blanas A, Sidiropoulos P, Makrigiannakis A, Bertsias G, Boumpas DT, Verginis P. IFNα Impairs Autophagic Degradation of mtDNA Promoting Autoreactivity of SLE Monocytes in a STING-Dependent Fashion. Cell Rep 2018;25:921-933.e5. [PMID: 30355498 DOI: 10.1016/j.celrep.2018.09.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 13.3] [Reference Citation Analysis]
17 Abbruzzese C, Matteoni S, Signore M, Cardone L, Nath K, Glickson JD, Paggi MG. Drug repurposing for the treatment of glioblastoma multiforme. J Exp Clin Cancer Res 2017;36:169. [PMID: 29179732 DOI: 10.1186/s13046-017-0642-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
18 Webb J, Abraham A. Complex Transfusion Issues in Pediatric Hematopoietic Stem Cell Transplantation. Transfus Med Rev 2016;30:202-8. [PMID: 27439965 DOI: 10.1016/j.tmrv.2016.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
19 Sin SH, Eason AB, Bigi R, Kim Y, Kang S, Tan K, Seltzer TA, Venkataramanan R, An H, Dittmer DP. Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections. J Virol 2018;92:e01138-18. [PMID: 30021906 DOI: 10.1128/JVI.01138-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Qi YY, Zhou XJ, Cheng FJ, Hou P, Ren YL, Wang SX, Zhao MH, Yang L, Martinez J, Zhang H. Increased autophagy is cytoprotective against podocyte injury induced by antibody and interferon-α in lupus nephritis. Ann Rheum Dis 2018;77:1799-809. [PMID: 30209031 DOI: 10.1136/annrheumdis-2018-213028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
21 Ji L, Xie W, Zhang Z. Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Semin Arthritis Rheum 2020;50:1073-80. [PMID: 32911286 DOI: 10.1016/j.semarthrit.2020.07.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood 2020;135:472-90. [PMID: 31756253 DOI: 10.1182/blood.2019003599] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
23 Grace RF, Neunert C. Second-line therapies in immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2016;2016:698-706. [PMID: 27913549 DOI: 10.1182/asheducation-2016.1.698] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
24 Walter JE, Farmer JR, Foldvari Z, Torgerson TR, Cooper MA. Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies. J Allergy Clin Immunol Pract 2016;4:1089-100. [PMID: 27836058 DOI: 10.1016/j.jaip.2016.08.004] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
25 Tasian SK, Casas JA, Posocco D, Gandre-Babbe S, Gagne AL, Liang G, Loh ML, Weiss MJ, French DL, Chou ST. Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. Leukemia 2019;33:181-90. [PMID: 29884903 DOI: 10.1038/s41375-018-0169-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
26 Chan AY, Torgerson TR. Primary immune regulatory disorders: a growing universe of immune dysregulation. Curr Opin Allergy Clin Immunol 2020;20:582-90. [PMID: 32941318 DOI: 10.1097/ACI.0000000000000689] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
27 Abdelbaky MA, Ragab IA, AbouZeid AA, Mohammad SA, Dahab MM, Elsherbeny M, Safaan HA. Sirolimus: A Rescue Drug to Control Complications of Extensive Venous Malformation. European J Pediatr Surg Rep 2020;8:e90-4. [PMID: 33335826 DOI: 10.1055/s-0040-1716895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Peng L, Wu C, Hong R, Sun Y, Qian J, Zhao J, Wang Q, Tian X, Wang Y, Li M, Zeng X. Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis. Ther Adv Musculoskelet Dis 2020;12:1759720X20953336. [PMID: 32973935 DOI: 10.1177/1759720X20953336] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Aylan Gelen S, Kara B, Eser Şimsek I, Güngör M, Zengin E, Sarper N. Autoimmune Hemolytic Anemia Due to Spondyloenchondrodysplasia with Spastic Paraparesis and Intracranial Calcification due to Mutation in ACP5. J Pediatr Genet. [DOI: 10.1055/s-0041-1736560] [Reference Citation Analysis]
30 Lambert MP. Presentation and diagnosis of autoimmune lymphoproliferative syndrome (ALPS). Expert Rev Clin Immunol 2021;17:1163-73. [PMID: 34503378 DOI: 10.1080/1744666X.2021.1978842] [Reference Citation Analysis]
31 Feng Y, Chen X, Cassady K, Zou Z, Yang S, Wang Z, Zhang X. The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside. Front Oncol 2020;10:611690. [PMID: 33489922 DOI: 10.3389/fonc.2020.611690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
32 Consonni F, Gambineri E, Favre C. ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies. Ann Hematol. [DOI: 10.1007/s00277-022-04761-7] [Reference Citation Analysis]
33 Li E, Grimes AB, Rider NL, Mahoney DH, Fleisher TA, Shearer WT. Diagnostic dilemma: ALPS versus Evans syndrome. Clin Immunol 2017;183:247-8. [PMID: 28802957 DOI: 10.1016/j.clim.2017.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
34 Wu C, Wang Q, Xu D, Li M, Zeng X. Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. Rheumatology (Oxford) 2021;60:2629-34. [PMID: 33200217 DOI: 10.1093/rheumatology/keaa645] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Pesenacker AM, Cook L, Levings MK. The role of FOXP3 in autoimmunity. Curr Opin Immunol 2016;43:16-23. [PMID: 27544816 DOI: 10.1016/j.coi.2016.07.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
36 Tuijnenburg P, Aan de Kerk DJ, Jansen MH, Morris B, Lieftink C, Beijersbergen RL, van Leeuwen EMM, Kuijpers TW. High-throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells. Eur J Immunol 2020;50:73-85. [PMID: 31621069 DOI: 10.1002/eji.201948241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wiersma M, Henning RH, Brundel BJ. Derailed Proteostasis as a Determinant of Cardiac Aging. Can J Cardiol 2016;32:1166.e11-20. [PMID: 27345610 DOI: 10.1016/j.cjca.2016.03.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
38 Nozawa A, Ozeki M, Yasue S, Endo S, Kawamoto N, Ohnishi H, Fumino S, Furukawa T, Tajiri T, Maekawa T, Fujino A, Souzaki R, Fukao T. Immunologic Effects of Sirolimus in Patients With Vascular Anomalies. Journal of Pediatric Hematology/Oncology 2020;42:e355-60. [DOI: 10.1097/mph.0000000000001650] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Neunert CE, Despotovic JM. Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature. Pediatr Blood Cancer 2019;66:e27569. [PMID: 30537439 DOI: 10.1002/pbc.27569] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
40 Rotz SJ, Ware RE, Kumar A. Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults. Pediatr Blood Cancer 2018;65:e27260. [PMID: 29856527 DOI: 10.1002/pbc.27260] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
41 Rae W, Ramakrishnan KA, Gao Y, Ashton-key M, Pengelly RJ, Patel SV, Ennis S, Williams AP, Faust SN. Precision treatment with sirolimus in a case of activated phosphoinositide 3-kinase δ syndrome. Clinical Immunology 2016;171:38-40. [DOI: 10.1016/j.clim.2016.07.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
42 Farmer JR, Foldvari Z, Ujhazi B, De Ravin SS, Chen K, Bleesing JJH, Schuetz C, Al-Herz W, Abraham RS, Joshi AY, Costa-Carvalho BT, Buchbinder D, Booth C, Reiff A, Ferguson PJ, Aghamohammadi A, Abolhassani H, Puck JM, Adeli M, Cancrini C, Palma P, Bertaina A, Locatelli F, Di Matteo G, Geha RS, Kanariou MG, Lycopoulou L, Tzanoudaki M, Sleasman JW, Parikh S, Pinero G, Fischer BM, Dbaibo G, Unal E, Patiroglu T, Karakukcu M, Al-Saad KK, Dilley MA, Pai SY, Dutmer CM, Gelfand EW, Geier CB, Eibl MM, Wolf HM, Henderson LA, Hazen MM, Bonfim C, Wolska-Kuśnierz B, Butte MJ, Hernandez JD, Nicholas SK, Stepensky P, Chandrakasan S, Miano M, Westermann-Clark E, Goda V, Kriván G, Holland SM, Fadugba O, Henrickson SE, Ozen A, Karakoc-Aydiner E, Baris S, Kiykim A, Bredius R, Hoeger B, Boztug K, Pashchenko O, Neven B, Moshous D, Villartay JP, Bousfiha AA, Hill HR, Notarangelo LD, Walter JE. Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency. J Allergy Clin Immunol Pract 2019;7:1970-1985.e4. [PMID: 30877075 DOI: 10.1016/j.jaip.2019.02.038] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
43 Kalfa TA. Warm antibody autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2016;2016:690-7. [PMID: 27913548 DOI: 10.1182/asheducation-2016.1.690] [Cited by in Crossref: 44] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
44 Neely JA, Dvorak CC, Pantell MS, Melton A, Huang JN, Shimano KA. Autoimmune Cytopenias in Pediatric Hematopoietic Cell Transplant Patients. Front Pediatr 2019;7:171. [PMID: 31131266 DOI: 10.3389/fped.2019.00171] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
45 Schmidt RE, Grimbacher B, Witte T. Autoimmunity and primary immunodeficiency: two sides of the same coin? Nat Rev Rheumatol 2017;14:7-18. [PMID: 29255211 DOI: 10.1038/nrrheum.2017.198] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 11.2] [Reference Citation Analysis]
46 Bevacqua M, Baldo F, Pastore S, Valencic E, Tommasini A, Maestro A, Rabusin M, Arbo A, Barbi E. Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature. Pediatr Drugs 2019;21:185-93. [DOI: 10.1007/s40272-019-00337-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
47 Westermann-Clark E, Meehan CA, Meyer AK, Dasso JF, Amre D, Ellison M, Patel B, Betensky M, Hauk CI, Mayer J, Metts J, Leiding JW, Sriaroon P, Kumar A, Ayala I, Walter JE. Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort. Front Immunol 2021;12:649182. [PMID: 33968040 DOI: 10.3389/fimmu.2021.649182] [Reference Citation Analysis]
48 Kong J, Wu K, Ji Y, Chen K, Zhang J, Sun H, Liang Y, Liang W, Chang Y, Cheng J, Tong J, Li J, Xing G, Chen G. Enhanced Bioavailability by Orally Administered Sirolimus Nanocrystals. ACS Appl Bio Mater 2019;2:4612-21. [DOI: 10.1021/acsabm.9b00695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
49 Li Y, Wu D, Yang X, Zhou S. Immunotherapeutic Potential of T Memory Stem Cells. Front Oncol 2021;11:723888. [PMID: 34604060 DOI: 10.3389/fonc.2021.723888] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Voulgaridou A, Kalfa TA. Autoimmune Hemolytic Anemia in the Pediatric Setting. J Clin Med 2021;10:E216. [PMID: 33435309 DOI: 10.3390/jcm10020216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Allen CE. ALPS DNT cells: active senior living with mTOR. Blood 2016;128:152-152. [DOI: 10.1182/blood-2016-05-713032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Ducassou S, Gourdonneau A, Fernandes H, Leverger G, Pasquet M, Fouyssac F, Bayart S, Bertrand Y, Michel G, Jeziorski E, Thomas C, Abouchallah W, Viard F, Guitton C, Cheikh N, Pellier I, Carausu L, Droz C, Leblanc T, Aladjidi N; Centre de Référence National des Cytopénies Auto-immunes de l’Enfant (CEREVANCE). Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years. Br J Haematol 2020;189:931-42. [PMID: 32130726 DOI: 10.1111/bjh.16448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
53 Rao VK. Serendipity in splendid isolation: rapamycin. Blood 2016;127:5-6. [PMID: 26744433 DOI: 10.1182/blood-2015-11-679829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
54 Williams O, Bhat R, Badawy SM. Sirolimus for treatment of refractory primary warm autoimmune hemolytic anemia in children. Blood Cells Mol Dis 2020;83:102427. [PMID: 32220699 DOI: 10.1016/j.bcmd.2020.102427] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
55 Arenas DJ, Floess K, Kobrin D, Pai RL, Srkalovic MB, Tamakloe MA, Rasheed R, Ziglar J, Khor J, Parente SAT, Pierson SK, Martinez D, Wertheim GB, Kambayashi T, Baur J, Teachey DT, Fajgenbaum DC. Increased mTOR activation in idiopathic multicentric Castleman disease. Blood 2020;135:1673-84. [PMID: 32206779 DOI: 10.1182/blood.2019002792] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
56 Gao S, Liang X, Wang H, Bao B, Zhang K, Zhu Y, Shao Q. Stem cell-like memory T cells: A perspective from the dark side. Cell Immunol 2021;361:104273. [PMID: 33422699 DOI: 10.1016/j.cellimm.2020.104273] [Reference Citation Analysis]
57 George LA, Teachey DT. Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children. Pediatr Drugs 2016;18:261-72. [DOI: 10.1007/s40272-016-0175-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
58 Vignesh P, Rawat A, Singh S. An Update on the Use of Immunomodulators in Primary Immunodeficiencies. Clin Rev Allergy Immunol 2017;52:287-303. [PMID: 27873163 DOI: 10.1007/s12016-016-8591-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
59 Kim TO, Despotovic JM. Primary and Secondary Immune Cytopenias: Evaluation and Treatment Approach in Children. Hematol Oncol Clin North Am 2019;33:489-506. [PMID: 31030815 DOI: 10.1016/j.hoc.2019.01.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
60 Banday AZ, Jindal AK, Tyagi R, Singh S, Patra PK, Kumar Y, Suri D, Rawat A. Refractory Autoimmune Cytopenia in a Young Boy with a Novel LRBA Mutation Successfully Managed with Sirolimus. J Clin Immunol 2020;40:1184-6. [PMID: 32915433 DOI: 10.1007/s10875-020-00835-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
61 Chai L, Fan X, Zuo Y, Zhang B, Nie G, Xie N, Xie Z, Zhang H. Low-dimensional nanomaterials enabled autoimmune disease treatments: Recent advances, strategies, and future challenges. Coordination Chemistry Reviews 2021;432:213697. [DOI: 10.1016/j.ccr.2020.213697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Jaime-Pérez JC, Aguilar-Calderón PE, Salazar-Cavazos L, Gómez-Almaguer D. Evans syndrome: clinical perspectives, biological insights and treatment modalities. J Blood Med 2018;9:171-84. [PMID: 30349415 DOI: 10.2147/JBM.S176144] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
63 Audia S, Grienay N, Mounier M, Michel M, Bonnotte B. Evans' Syndrome: From Diagnosis to Treatment. J Clin Med 2020;9:E3851. [PMID: 33260979 DOI: 10.3390/jcm9123851] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
64 King JR, Notarangelo LD, Hammarström L. An appraisal of the Wilson & Jungner criteria in the context of genomic-based newborn screening for inborn errors of immunity. J Allergy Clin Immunol 2021;147:428-38. [PMID: 33551024 DOI: 10.1016/j.jaci.2020.12.633] [Reference Citation Analysis]
65 Sanchez-Lopez E, Cheng A, Guma M. Can Metabolic Pathways Be Therapeutic Targets in Rheumatoid Arthritis? J Clin Med 2019;8:E753. [PMID: 31137815 DOI: 10.3390/jcm8050753] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
66 Guffroy A, Gies V, Martin M, Korganow AS. [Primary immunodeficiency and autoimmunity]. Rev Med Interne 2017;38:383-92. [PMID: 27889323 DOI: 10.1016/j.revmed.2016.10.388] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Xing L, Wang Y, Liu H, Gao S, Shao Q, Yue L, Liu Z, Wang H, Shao Z, Fu R. Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy. Front Oncol 2021;11:798352. [PMID: 35004324 DOI: 10.3389/fonc.2021.798352] [Reference Citation Analysis]
68 Sharma S, Hussain MS, Agarwal N, Bhurani D, Khan MA, Ahmad Ansari MA. Efficacy of sirolimus for treatment of autoimmune lymphoproliferative syndrome: a systematic review of open label clinical studies. Expert Opinion on Orphan Drugs 2021;9:219-26. [DOI: 10.1080/21678707.2021.1970523] [Reference Citation Analysis]
69 Guffroy A, Mourot-Cottet R, Gérard L, Gies V, Lagresle C, Pouliet A, Nitschké P, Hanein S, Bienvenu B, Chanet V, Donadieu J, Gardembas M, Karmochkine M, Nove-Josserand R, Martin T, Poindron V, Soulas-Sprauel P, Rieux-Laucat F, Fieschi C, Oksenhendler E, André-Schmutz I, Korganow AS; DEFI study group. Neutropenia in Patients with Common Variable Immunodeficiency: a Rare Event Associated with Severe Outcome. J Clin Immunol 2017;37:715-26. [PMID: 28842786 DOI: 10.1007/s10875-017-0434-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
70 Chandrakasan S, Chandra S, Davila Saldana BJ, Torgerson TR, Buchbinder D. Primary immune regulatory disorders for the pediatric hematologist and oncologist: A case‐based review. Pediatr Blood Cancer 2019;66:e27619. [DOI: 10.1002/pbc.27619] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
71 Li W, Sivakumar R, Titov AA, Choi SC, Morel L. Metabolic Factors that Contribute to Lupus Pathogenesis. Crit Rev Immunol 2016;36:75-98. [PMID: 27480903 DOI: 10.1615/CritRevImmunol.2016017164] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
72 Völkl S, Rensing-Ehl A, Allgäuer A, Schreiner E, Lorenz MR, Rohr J, Klemann C, Fuchs I, Schuster V, von Bueren AO, Naumann-Bartsch N, Gambineri E, Siepermann K, Kobbe R, Nathrath M, Arkwright PD, Miano M, Stachel KD, Metzler M, Schwarz K, Kremer AN, Speckmann C, Ehl S, Mackensen A. Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome. Blood 2016;128:227-38. [PMID: 27099149 DOI: 10.1182/blood-2015-11-685024] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
73 Golwala ZM, Taur P, Pandrowala A, Chandak S, Desai M. Sirolimus-A targeted therapy for Rosai-Dorfman disease. Pediatr Blood Cancer 2019;66:e27994. [PMID: 31524314 DOI: 10.1002/pbc.27994] [Reference Citation Analysis]
74 Ciliberto G, Mancini R, Paggi MG. Drug repurposing against COVID-19: focus on anticancer agents. J Exp Clin Cancer Res 2020;39:86. [PMID: 32398164 DOI: 10.1186/s13046-020-01590-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 14.5] [Reference Citation Analysis]
75 Rae W, Ward D, Mattocks CJ, Gao Y, Pengelly RJ, Patel SV, Ennis S, Faust SN, Williams AP. Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort. Clin Transl Immunology 2017;6:e155. [PMID: 28983403 DOI: 10.1038/cti.2017.38] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
76 Sulpizio ED, Raghunathan V, Shatzel JJ, Zilberman-Rudenko J, Worrest T, Sheppard BC, DeLoughery TG. Long-term remission rates after splenectomy in adults with Evans syndrome compared to immune thrombocytopenia: A single-center retrospective study. Eur J Haematol 2020;104:55-8. [PMID: 31594025 DOI: 10.1111/ejh.13336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Scherlinger M, Tsokos GC. Reactive oxygen species: The Yin and Yang in (auto-)immunity. Autoimmun Rev 2021;20:102869. [PMID: 34118461 DOI: 10.1016/j.autrev.2021.102869] [Reference Citation Analysis]
78 Morel L. Immunometabolism in systemic lupus erythematosus. Nat Rev Rheumatol 2017;13:280-90. [PMID: 28360423 DOI: 10.1038/nrrheum.2017.43] [Cited by in Crossref: 97] [Cited by in F6Publishing: 95] [Article Influence: 19.4] [Reference Citation Analysis]
79 Tranfaglia MR, Thibodeaux C, Mason DJ, Brown D, Roberts I, Smith R, Guilliams T, Cogram P. Repurposing available drugs for neurodevelopmental disorders: The fragile X experience. Neuropharmacology 2019;147:74-86. [PMID: 29792283 DOI: 10.1016/j.neuropharm.2018.05.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
80 Miano M, Rotulo GA, Palmisani E, Giaimo M, Fioredda F, Pierri F, Pezzulla A, Licciardello M, Terranova P, Lanza T, Cappelli E, Maggiore R, Calvillo M, Micalizzi C, Russo G, Dufour C. Sirolimus as a rescue therapy in children with immune thrombocytopenia refractory to mycophenolate mofetil. Am J Hematol 2018;93:E175-7. [DOI: 10.1002/ajh.25119] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
81 Walkovich K, Connelly JA. Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation. Hematology Am Soc Hematol Educ Program 2021;2021:504-13. [PMID: 34889406 DOI: 10.1182/hematology.2021000285] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Xiao Z, Murakhovskaya I. Development of New Drugs for Autoimmune Hemolytic Anemia. Pharmaceutics 2022;14:1035. [DOI: 10.3390/pharmaceutics14051035] [Reference Citation Analysis]
83 Pincez T, Neven B, Le Pointe HD, Varlet P, Fernandes H, Gareton A, Leverger G, Leblanc T, Chambost H, Michel G, Pasquet M, Millot F, Hermine O, Mathian A, Hully M, Zephir H, Hamidou M, Durand JM, Perel Y, Landman-Parker J, Rieux-Laucat F, Aladjidi N. Neurological Involvement in Childhood Evans Syndrome. J Clin Immunol 2019;39:171-81. [PMID: 30671780 DOI: 10.1007/s10875-019-0594-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
84 Panigrahi A, Clark A, Myers J, Raj A. A novel immunomodulatory treatment involving mycophenolate mofetil and corticosteroids for pediatric autoimmune cytopenias: Panigrahi et al. Pediatr Blood Cancer 2017;64:287-93. [DOI: 10.1002/pbc.26210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
85 Barzaghi F, Minniti F, Mauro M, Bortoli M, Balter R, Bonetti E, Zaccaron A, Vitale V, Omrani M, Zoccolillo M, Brigida I, Cicalese MP, Degano M, Hershfield MS, Aiuti A, Bondarenko AV, Chinello M, Cesaro S. ALPS-Like Phenotype Caused by ADA2 Deficiency Rescued by Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2018;9:2767. [PMID: 30692987 DOI: 10.3389/fimmu.2018.02767] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
86 Togashi Y, Nishikawa H. Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation. Curr Top Microbiol Immunol 2017;410:3-27. [PMID: 28879523 DOI: 10.1007/82_2017_58] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
87 Klemann C, Esquivel M, Magerus-Chatinet A, Lorenz MR, Fuchs I, Neveux N, Castelle M, Rohr J, da Cunha CB, Ebinger M, Kobbe R, Kremens B, Kollert F, Gambineri E, Lehmberg K, Seidel MG, Siepermann K, Voelker T, Schuster V, Goldacker S, Schwarz K, Speckmann C, Picard C, Fischer A, Rieux-Laucat F, Ehl S, Rensing-Ehl A, Neven B. Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome. Haematologica 2017;102:e52-6. [PMID: 27789675 DOI: 10.3324/haematol.2016.153411] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
88 Lai CMB, Setiadi A, Barlas A, Kanani A, Pourshahnazari P, Leitch HA, Metzger DL, Merkeley H, Biggs CM; CAUSES Study. Targeted treatment of immune thrombocytopenia in CTLA-4 insufficiency: a case report. Br J Haematol 2021. [PMID: 34628649 DOI: 10.1111/bjh.17866] [Reference Citation Analysis]
89 Li H, Ji J, Du Y, Huang Y, Gu H, Chen M, Wu R, Han B. Sirolimus is effective for primary relapsed/refractory autoimmune cytopenia: a multicenter study. Exp Hematol 2020;89:87-95. [PMID: 32771553 DOI: 10.1016/j.exphem.2020.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
90 Bonam SR, Wang F, Muller S. Autophagy: A new concept in autoimmunity regulation and a novel therapeutic option. J Autoimmun 2018;94:16-32. [PMID: 30219390 DOI: 10.1016/j.jaut.2018.08.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
91 Casamayor-Polo L, López-Nevado M, Paz-Artal E, Anel A, Rieux-Laucat F, Allende LM. Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS). Crit Rev Clin Lab Sci 2021;58:253-74. [PMID: 33356695 DOI: 10.1080/10408363.2020.1855623] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
92 Wyman B, Perl A. Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases. Curr Opin Rheumatol 2020;32:184-91. [PMID: 31895126 DOI: 10.1097/BOR.0000000000000687] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
93 Phillips AD, Kakkis JJ, Tsao PY, Pierson SK, Fajgenbaum DC. Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO. J Cell Mol Med 2022. [PMID: 35488725 DOI: 10.1111/jcmm.17251] [Reference Citation Analysis]
94 Grimes AB, Kim TO, Kirk SE, Flanagan J, Lambert MP, Grace RF, Despotovic JM. Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation. Eur J Haematol 2021;106:783-7. [PMID: 33570766 DOI: 10.1111/ejh.13600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Gaefke CL, Metts J, Imanirad D, Nieves D, Terranova P, Dell'Orso G, Gambineri E, Miano M, Lockey RF, Walter JE, Westermann-Clark E. Case Report: A Novel Pathogenic Missense Mutation in FAS: A Multi-Generational Case Series of Autoimmune Lymphoproliferative Syndrome. Front Pediatr 2021;9:624116. [PMID: 33816397 DOI: 10.3389/fped.2021.624116] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Kruizinga MD, van Tol MJ, Bekker V, Netelenbos T, Smiers FJ, Bresters D, Jansen-hoogendijk AM, van Ostaijen-ten Dam MM, Kollen WJ, Zwaginga JJ, Lankester AC, Bredius RG. Risk Factors, Treatment, and Immune Dysregulation in Autoimmune Cytopenia after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. Biology of Blood and Marrow Transplantation 2018;24:772-8. [DOI: 10.1016/j.bbmt.2017.12.782] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
97 Rössler J, Baselga E, Davila V, Celis V, Diociaiuti A, El Hachem M, Mestre S, Haeberli D, Prokop A, Hanke C, Loichinger W, Quéré I, Baumgartner I, Niemeyer CM, Kapp FG. Severe adverse events during sirolimus "off-label" therapy for vascular anomalies. Pediatr Blood Cancer 2021;68:e28936. [PMID: 33580918 DOI: 10.1002/pbc.28936] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
98 Feng Y, Xiao Y, Yan H, Wang P, Zhu W, Cassady K, Zou Z, Wang K, Chen T, Quan Y, Wang Z, Yang S, Wang R, Li X, Gao L, Zhang C, Liu Y, Kong P, Gao L, Zhang X. Sirolimus as Rescue Therapy for Refractory/Relapsed Immune Thrombocytopenia: Results of a Single-Center, Prospective, Single-Arm Study. Front Med (Lausanne) 2020;7:110. [PMID: 32296709 DOI: 10.3389/fmed.2020.00110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
99 Müller-calleja N, Hollerbach A, Häuser F, Canisius A, Orning C, Lackner KJ. Antiphospholipid antibody-induced cellular responses depend on epitope specificity : implications for treatment of antiphospholipid syndrome. J Thromb Haemost 2017;15:2367-76. [DOI: 10.1111/jth.13865] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
100 Banday AZ, Jindal AK. Comment on: Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. Rheumatology (Oxford) 2021;60:e211-2. [PMID: 33410455 DOI: 10.1093/rheumatology/keaa918] [Reference Citation Analysis]
101 Eriksson P, Wallin P, Sjöwall C. Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus. Front Pharmacol 2019;10:82. [PMID: 30787878 DOI: 10.3389/fphar.2019.00082] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
102 Chen Z, Liu X, Chen M, Yang C, Han B. Successful sirolimus treatment of patients with pure red cell aplasia complicated with renal insufficiency. Ann Hematol 2020;99:737-41. [PMID: 32030447 DOI: 10.1007/s00277-020-03946-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
103 Nocerino A, Valencic E, Loganes C, Pelos G, Tommasini A. Low-dose sirolimus in two cousins with autoimmune lymphoproliferative syndrome-associated infection. Pediatr Int 2018;60:315-7. [PMID: 29480551 DOI: 10.1111/ped.13494] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
104 Yang C, Chen FF, Long ZB, Du YL, Li HM, Chen M, Han B. [Effect of sirolimus on erythropoiesis of K562 cell line and patients with pure red cell aplasia in vitro]. Zhonghua Xue Ye Xue Za Zhi 2018;39:310-3. [PMID: 29779328 DOI: 10.3760/cma.j.issn.0253-2727.2018.04.011] [Cited by in F6Publishing: 2] [Reference Citation Analysis]